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Abstract
Background: Differentiation of human embryonic stem cells into endothelial cells (hESC-ECs) has the potential to provide an
unlimited source of cells for novel transplantation therapies of ischemic diseases by supporting angiogenesis and
vasculogenesis. However, the endothelial differentiation efficiency of the conventional embryoid body (EB) method is low
while the 2-dimensional method of co-culturing with mouse embryonic fibroblasts (MEFs) require animal product, both of
which can limit the future clinical application of hESC-ECs. Moreover, to fully understand the beneficial effects of stem cell
therapy, investigators must be able to track the functional biology and physiology of transplanted cells in living subjects
over time.
Methodology: In this study, we developed an extracellular matrix (ECM) culture system for increasing endothelial
differentiation and free from contaminating animal cells. We investigated the transcriptional changes that occur during
endothelial differentiation of hESCs using whole genome microarray, and compared to human umbilical vein endothelial
cells (HUVECs). We also showed functional vascular formation by hESC-ECs in a mouse dorsal window model. Moreover, our
study is the first so far to transplant hESC-ECs in a myocardial infarction model and monitor cell fate using molecular
imaging methods.
Conclusion: Taken together, we report a more efficient method for derivation of hESC-ECs that express appropriate patterns
of endothelial genes, form functional vessels in vivo, and improve cardiac function. These studies suggest that hESC-ECs
may provide a novel therapy for ischemic heart disease in the future.
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Introduction
Ischemic heart disease is a leading cause of mortality and
morbidity worldwide. Current treatments fail to address the
underlying scarring and cell loss, which is a major cause of heart
failure after infarction [1,2]. Therapeutic angiogenesis and/or
vasculogenesis using cellular transplantation is a promising and
novel strategy to increase blood flow in patients with severe
ischemic heart disease and peripheral vascular disease. In several
studies related to peripheral vascular disease, endothelial progen-
itor cells (EPCs) derived from patients that are then used for
autologous transplantation therapy have been shown to foster the
formation of arterial collaterals and promote the regeneration of
ischemic tissues [3,4,5]. However, difficulties in obtaining
sufficient numbers of adult EPCs from patients, as well as
impaired function of these cells in patients with co-morbid
diseases, may limit autologous stem cell therapies [6,7]. With
their capacity for unlimited self-renewal and pluripotency, human
embryonic stem cells (hESCs) may provide an alternate source of
therapeutic cells by allowing the derivation of large numbers of
endothelial cells for various tissue repair and cell replacement
therapies.
Several methods have been used to successfully differentiate
hESCs into endothelial cells, including three-dimensional (3D)
embryoid body (EB) formation and two-dimensional (2D) culture
system [6,8,9,10,11,12]. However, the endothelial differentiation
efficiency of previous 3D embryoid body method is low and the
2D method by co-culture with mouse cells suffers from
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be introduced to increase the differentiation efficiency and ensure
animal free derived products. In this study, we developed an
extracellular matrix culture system for increasing endothelial
differentiation and ensuring animal free hESC-ECs. We designed
a staged protocol that involved EB formation (stage 1) and
expansion of endothelial lineage by subculturing EBs in collagen
(stage 2). We then derive a highly pure endothelial population by
CD31/CD144 double sorting using flow cytometry. In order to
define at a molecular level the changes occurring at each stage of
hESC differentiation to endothelial cell progeny, and to validate
that these cells are similar to human umbilical vein endothelial
cells (HUVECs), we also perform transcriptional profiling using
whole human genome microarrays and real-time PCR arrays.
Finally, to fully understand the beneficial effects of stem cell
therapy, one must also be able to track the transplanted cells in
living subjects over time in order to better understand their
behavior and function in vivo. Therefore, we performed multi-
modality imaging in a murine dorsal window model and a murine
myocardial ischemia model to assess hESC-EC fate and function.
Materials and Methods
Two-step in vitro differentiation of hESC-ECs
Undifferentiated hESCs (H9 line from Wicell, passages 35 to 45)
were grown on Matrigel-coated plates in mTeSR1 medium (Stem
Cell Technologies, Vancouver, BC, Canada) as previously
described [13]. To induce endothelial differentiation, undifferen-
tiated hESCs were cultured in differentiation medium containing
Iscove’s modified Dulbecco’s medium (IMDM) and 15% Knock-
out
TM Serum Replacement (Knockout
TM SR) (Invitrogen,
Carlsbad, CA), 16 BIT (BSA, insulin, transferring; Stem Cell
Technologies), 0.1 mM nonessential amino acids, 2 mM L-
glutamine, 450 mM monothioglycerol (Sigma, St. Louis, MO),
50 U/ml penicillin, and 50 mg/ml streptomycin, supplemented
with 20 ng/ml bFGF (R&D Systems Inc., Minneapolis) and
50 ng/ml VEGF (R&D Systems Inc.), in ultra-low attachment
plates (Corning Incorporated, Corning, NY) for the formation of
suspended embryoid bodies (EBs) as previously described [10,12].
EB sprouting differentiation in collagen type I was performed as
described [14], with minor modifications. Briefly, 12 days-old EBs
were harvested, and then suspended into rat tail collagen type I
(Becton Dickinson, San Jose, CA) at a final concentration of
1.5 mg/ml collagen. After thoroughly mixing EBs into collagen,
1.5 ml/well of mixture was added into six-well plate. The plates
were incubated at 37uC for 30 min, allowing gel polymerization
prior to addition of medium. After gel formation, each dish was
supplemented with EGM-2 medium (Lonza, Basel, Switzerland)
and 5% Knockout
TM SR with additional 50 ng/ml VEGF and
20 ng/ml bFGF. The cultures were then incubated for 3 days
without media change (Figure 1A).
Flow cytometry sorting (FCS) of hESC-ECs
Single cell suspension from hEB-sprouting was obtained by
treatment with 0.25% collagenase I (Invitrogen, Carlsbad, CA) at
37uC for 20–30 min, then with 0.56 units/ml Liberase Blendzyme
IV (Roche Diagnostics, Indianapolis) at 37uC for 10–20 minutes.
Cells were passed through a 40-mm cell strainer (BD Falcon, San
Diego) [15]. Cells were incubated with mouse anti-human CD31
(BD) and rabbit anti-human CD144 (Abcam, Cambridge, MA).
The CD31
+/CD144
+ cells were isolated using FACScan (Becton
Dickinson). To generate hESC-ECs, the isolated CD31
+/CD144
+
cells from hEB-sprouting were grown on 4 g/cm
2 human
fibronectin (Calbiochem, San Diego, CA) coated plates in EGM-
2 (Lonza) and 5% Knockout SR
TM with additional 5 ng/ml
VEGF. The medium was changed every 2–3 days.
Functional and biological characterization of hESC-ECs
Flow cytometry analysis, immunostaining, DiI-ac-LDL uptake
assay, and Matrigel assay were used to confirm endothelial cell
phenotype within these CD31
+/CD144
+ purified hES cells.
Antibodies used for flow cytometry analysis were phycoerythrin
(PE) conjugated anti-CD31, CD34 (BD Pharmingen) and
Allophycocyanin (APC) conjugated anti-KDR, CD133 (R&D
Systems), APC conjugated anti-mouse IgG2a, and rabbit anti-
human CD144 (Abcam, Cambridge, MA). The stained cells were
analyzed using FACS Vantage (Becton-Dickinson, MA). Dead
cells stained by propidium-iodide (PI) were excluded from the
analysis. Isotype-identical antibodies served as controls (BD
Pharmingen). For immunostaining, the cells were fixed with 4%
paraformaldehyde in PBS at room temperature for 15 minutes.
The fixed cells were permeated by 1% Triton 100 and incubated
with 2% BSA for 30 minutes to block nonspecific binding, and
stained for 1 hour with the primary antibodies: CD31 (BD
Pharmingen), CD144 (Abcam), and vWF (Chemicon International
Inc), respectively. The cells were then incubated for 30 minutes
with either Alexa 594-conjugated donkey anti-mouse secondary
antibody or Alexa 488-conjugated donkey anti-rabbit secondary
antibody (Invitrogen), and counter stained with DAPI. Immuno-
staining of EBs and EB sproutings were performed as previously
described with minor modifications [14]. The EBs were fixed in
methanol and DMSO (4:1) at 4uC overnight. For staining, the
rehydrated EBs were first blocked by two incubations in PBSBT
(2% BSA and 0.2% Tween-20 in PBS), then with PBSBT
containing mouse anti-human MoAb CD31 (BD Pharmingen) or
rabbit anti-human CD144 (Abcam, Cambridge, MA) overnight at
4uC. The EBs were washed five times in PBSBT each for 1 hour at
4uC for the initial three washes and at room temperature for the
final two. The primary antibody was labeled by incubating the EBs
with Alexa 594-conjugated donkey anti-mouse IgG or Alexa 488-
conjugated donkey anti-rabbit IgG (Invitrogen) in PBSBT
overnight at 4uC and nuclear counterstained with DAPI.
For DiI-ac-LDL uptake assay, hESC-ECs were incubated with
10 mg/ml of DiI-Ac-LDL (Molecular Probes, Eugene, OR) at
37uC for 6 hours. After washing with PBS twice, cells were fixed
and counterstained with DAPI (4, 6-diamidino-2-phenylindole) as
described [11]. The formation of endothelial tubes was assessed by
seeding cells in 24-well plates coated with Matrigel (BD
Pharmingen) and incubating them at 37u for 12 hours as described
[16].
Microarray hybridization and data acquisition
Total RNA samples were isolated in Trizol (Invitrogen) followed
by purification over a Qiagen RNeasy column (Qiagen) from
undifferentiated hESCs, day 12 EBs, hESC-ECs (after CD31/
CD144 sort), and HUVECs. Four samples from each group (for a
total of 16 unique samples) were harvested for RNA isolation.
Using Agilent Low RNA Input Fluorescent Linear Amplification
Kits, cDNA was reverse transcribed from each of 16 RNA samples
representing four biological quadruplicates, as well as the pooled
reference control, and cRNA was then transcribed and fluores-
cently labeled with Cy5/Cy3. cRNA was purified using an
RNeasy kit (Qiagen, Valencia, CA, USA). 825 ng of Cy3- and
Cy5- labeled and amplified cRNA was hybridized to Agilent
4644K whole human genome microarrays (G4112F) and
processed according to the manufacturer’s instructions. The array
was scanned using Agilent G2505B DNA microarray scanner. The
image files were extracted using Agilent Feature Extraction
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PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8443Figure 1. Specification of hESC differentiation into endothelial lineage. (A) An outline of the protocol used for the differentiation of hESCs
to the endothelial lineage. Undifferentiated hESCs were grown to 60%–70% confluence on Matrigel and subcultured in low attachment dish with
differentiation medium supplement VEGF and bFGF, shown as day 0. At day 15, EBs in collagen were collected and digested and CD31+/CD144+ cells
were isolated by FACS and then sub-cultured in EGM-2 medium with 5% Knockout SRTM to expand and induce endothelial maturation. (B) Whole-
mount immunochemistry of day-12 EB. Areas of CD31 (red) and CD144 (green) expression within EBs are organized in elongated clusters and
channels. Cell nuclei stained with DAPI (blue). Scale bars=100 mm. (C) Endothelial differentiation of sprouting EBs in collagen. Representative
sprouting EBs after 3 days of culturing in collagen matrix (upper panel, left). Whole-mount immunostaining shows CD31 sprouting with channel-like
vessel structures and CD31 cell clumps (upper panel). These sproutings are also CD31 and CD144 double positive. Scale bars=20 mm (top panel, right
one) and 100 mm (others). (D) Kinetic expression of CD31 and CD144 during the two-step hESC differentiation procedures. CD31/CD144 expression
was triggered and increased from 1–3% to 10–15% after EBs were subcultured in collagen. hESC-ECs were enriched by isolation CD31+/CD144+ cells
after FACS (right panel). Experiments were performed in triplicates.
doi:10.1371/journal.pone.0008443.g001
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and dye-normalization. The data were analyzed using GeneSpring
GX 7.3.1. (Agilent Technologies, Santa Clara, CA) with multiple
testing correction to identify genes which had statistically significant
changes in expression between stages, and K-means clustering to
identify clusters of genes having unique temporal expression
profiles. For hierarchical clustering, we used Pearson correlation
for similarity measure and average linkage clustering. Gene
Ontology (GO) overrepresentation analysis was performed also
using the GeneSpring software. For confirmation of microarray
results, RT-PCR assays were performed using the human
endothelial cell biology RT
2 Profiler
TM PCR Array (SuperArray
Bioscience, Frederick, MD) on an ABI PRISM 7900 HT (Applied
Biosystems, Foster City, CA). Data analysis is available at the
company website: http://www.superarray.com/pcr/arrayanalysis.
php.
In vivo angiogenesis of hESC-ECs
To track transplanted cells in vivo, hESCs were transduced with
a self-inactivating lentiviral vector carrying a human ubiquitin
promoter driving firefly luciferase and enhanced green fluores-
cence protein (Fluc-eGFP) double fusion reporter gene as
described [12]. For Matrigel plug analysis, 1610
6 hESC-ECs
suspended in 1 ml Matrigel were subcutaneous injected into SCID
Beige mice (n=5) and plugs were harvested at day 14 [17]. For
dorsal skin fold chamber (n=10 animals), 1610
6 hESC-ECs were
suspended in 1 ml solution of rat-tail type I collagen (at final
concentration 1.5 mg/ml) and Matrigel (1:1 ratio) at 4uC. The cell
suspension was pipetted into 12-well plates and warmed to 37uC
for 30 minutes to allow polymerization of collagen and Matrigel
and 1 ml EGM-2 medium with 5% Knockout SR
TM was added
after that. After one day of culture in 5% CO2, a skin puncher was
applied to create circular disk-shape pieces of the construct (8-mm
diameter), and they were implanted into the dorsal skin fold
windows in SCID mice. The titanium dorsal skin fold chamber
(APJ Trading Co. Inc, Ventura, Ca) surgically mounted onto each
mouse was described previously [18]. Briefly, mice were
anesthetized with inhaled isoflurane (2%–3%), and two symmet-
rical titanium frames were implanted to sandwich the extended
double layer of the skin. One layer was removed in a 10-mm-
diameter circular area. The remaining layer, consisting of
epidermis, subcutaneous tissue, and striated skin muscle, was
covered with a glass coverslip incorporated in one of the titanium
frames. The animals were housed one per cage and had free access
to water and food throughout the experiment. A recovery period
of 2 days was allowed before the collagen/Matrigel patch was
transplanted. Multiple laser-scanning intravital microscopy (IV-
100, Olympus, Center Valley, PA) was used to visualize and
quantify the morphological changes of Fluc-eGFP positive hESC-
ECs. The perfused vessels were highlighted by vein injection of
Angiosense 680 (VisEn Medical, Woburn, MA), indicating the
formation of functional engineered vessels [19].
Transplantation of hESC-ECs into ischemic myocardium
Animal protocols were approved by the Stanford University
Animal Care and Use Committee guidelines. All surgical
procedures were performed on 8–10 week old female SCID Beige
mice (Charles River Laboratories, Wilmington, MA) by a single
experienced micro-surgeon. Following induction with inhaled
isoflurane (2% to 3%), mice were intubated and ventilated and
anesthesia was maintained with inhaled isoflurane (1% to 2.5%). A
left thoracotomy was performed followed by ligation of the middle
of left anterior descending (LAD) artery for 30 minutes followed by
reperfusion. Infarction was visually confirmed by blanching of the
anterolateral region of the left ventricle along with dyskinesis. After
30 minutes, 1610
6 hESC-ECs stably expressing eGFP-Fluc were
injected intramyocardially into 3 sites near the peri-infarct zone at
20 ml of total volume (n=28). Control animals received PBS
injection instead (n=15). For sham operated animals (n=5), open
thoracotomy was performed but without ligation of the LAD
artery.
Bioluminescence imaging of transplanted cell survival
Cardiac bioluminescence imaging was performed using the
Xenogen IVIS 200 system by a blinded investigator (XX). After
intraperitoneal injection of the reporter probe D-Luciferin
(150 mg Luciferin/kg body weight), animals were imaged for 1–
10 minutes. The same mice were imaged for up to 8 weeks.
Bioluminescence signal was quantified in units of maximum
photons per second per cm square per steridian (photons/sec/
cm
2/sr) as described [16].
Left ventricular functional analysis with echocardiogram
and pressure-volume (PV) loop
Animals were scanned on baseline (day 27) and days 2, 14, 28,
and 56, post-operatively by a blinded investigator (MH) using the
Siemens-Acuson Sequoia C512 system equipped with a multi-
frequency (8–14 MHz) 15L8 transducer. Animals were anesthe-
tized with inhaled 2% isoflurane. Analysis of M-mode images was
performed. Left ventricular end diastolic diameter (LVEDd) and
end-systolic diameter (LVESd) were measured and used to
calculate fractional shortening (FS) by the following formula:
FS=[LVEDd2LVESd]/LVEDd [16]. At the end of the study
(day 56), invasive hemodynamic measurements were performed as
described [20]. Briefly, after midline neck incision, a conductance
1.4 conductance catheter (Millar Instruments, Houston, TX, USA)
was introduced into the left ventricle through the right carotid
artery. After stabilization, the signals were continuously recorded
at a sampling rate of 1000/s using pressure-volume conductance
system coupled to a PowerLab/4SP analog to digital converter
(ADInstruments). Data were analyzed by using a cardiac pressure-
volume analysis program (PVAN 3.4; Millar Instruments,
Houston, TX, USA) and Chart/Scope Software (AD Instruments,
Colorado Springs, CO, USA).
Positron emission tomography (PET) imaging of cardiac
viability
Small animal microPET imaging was carried out at day 27
(baseline) and days 2, 14, 28, and 56, post-operatively. Mice were
fasted for 3 hours prior to radioisotope injection and then were
injected with 140617 mCi of F18-fluorodeoxyglucose ([
18F]-
FDG) via the tail vein. At 45 to 60 minutes post-injection,
animals were anesthetized with inhaled 2% isoflurane and
imaged with a Vista microPET system (GE Health Care,
Chalfont St. Giles, United Kingdom). Images were reconstructed
by filtered back projection (FBP) and analyzed by image software
Amide (http://amide.sourceforge.net/index.html). Three-dimen-
sional regions of interest (ROIs) were drawn encompassing the
heart. Counts/pixel/min were converted to counts/ml/min
(assuming a tissue density of 1 g/ml) with a calibration constant
derived from scanning a cylindrical phantom [21]. For each ROI,
counts/ml/min were then converted to counts/gram/min and
divided by the injected dose to obtain the image ROI-derived
[
18F]-FDG percentage injected dose per gram of heart (% ID/g).
To measure the myocardial infarction size, [
18F]-FDG PET
images were assembled into polar maps [22]. The size of
perfusion defects was measured as the myocardium with 50% of
hESC-Derived Endothelial Cells
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polar map by GE Healthcare Advantage Workstation (GE
Healthcare, UK).
Histological analysis
Explanted hearts from study and control groups were embedded
into OCT compound (Miles Scientific). Frozen sections (5 mm
thick) were processed for immunostaining. To track GFP
+ hESC-
ECs in hearts, rabbit anti-GFP antibody (Invitrogen), rat anti-
mouse CD31 antibody (BD Pharmingen), anti-a-sarcomeric actin
(a-SA) antibody (Sigma), and anti-smooth muscle actin (SMA)
antibody (Labvision) were used. Alexa Fluor 488, Alexa Fluor 647,
and Alexa Fluor 594-conjugated secondary antibodies were
applied appropriately. DAPI was used for nuclear counterstaining.
To detect microvascular density (MVD) in the peri-infarct area, a
rat anti-mouse CD31 was used. The number of capillary vessels
was counted by a blinded investigator (FJ) in ten randomly selected
areas using a fluorescence microscope (200x). To measure
circumferential fibrosis area, Masson’s trichrome staining was
performed [23]. Explanted hearts from study and control groups
were harvested after euthanasia at 8 weeks after ischemia
reperfusion for assessment. Hearts embedded in paraffin were
cut into 5-mm slice, five to six sections from apex to base were
subjected to staining. Images were taken for each section to
calculate the fibrotic and nonfibrotic areas. The measurement of
area of fibrosis was determined by Image J software (NIH)
performed on 3 separate sections, and the averages were used for
statistics analysis.
Statistical analysis
Statistics were calculated using SPSS 16.0 (SPSS Inc., Chicago,
IL, USA). Descriptive statistics included mean and standard error.
Two-way repeated measures ANOVA and two-tailed Student’s t–
test were used. Differences were considered significant at P values
of ,0.05.
Results
Two step endothelial differentiation of hESCs
Major challenges for hESC-based therapies are the generation
of sufficient numbers of differentiated cells and animal product
free culture system. Several previous studies have shown that the
efficiency of hESC-EC differentiation by the 3D EB model is
about 1%–3% [10,12]. To increase endothelial differentiation
efficiency and avoid contamination from mouse embryonic
fibroblasts (MEFs), we developed a novel two-step differentiation
process with serum free culture system. hESCs were first cultured
in Petri dishes with differentiation medium for 12 days to induce
spontaneous EB formation (Figure 1A). Whole-mount immuno-
staining confirmed that CD31
+ and CD144
+ cells were organized
into channel-like structures within day-12 EBs (Figure 1B). These
data demonstrate that some cells within EBs can spontaneously
differentiate into endothelial cells that are then able to form blood
vessel-like structures, confirming previous reports from our lab and
others [8,10,12]. After step 1, EBs were embedded into collagen I
and subcultured for an additional 3 days. We observed sprouting
outgrowths from these EBs in collagen I that stained positive for
CD31/CD144 (Figure 1C). CD31/CD144 expression increased
swiftly to 10–15% after subculture in collagen as confirmed by
FACS analysis, as compared to only 1–2% using the conventional
EB culturing technique (Figure 1D). After sorting, CD31
+/
CD144
+ cells were further expanded as a nearly pure population
(9863%) and these cells were used for subsequent experiments.
Characterization of hESC-ECs
To determine whether hESC-ECs resemble HUVEC in
endothelial markers and angiogenesis potential, we expanded
FACS sorted CD31
+/CD144
+ cells on fibronectin-coated plates
supplemented with endothelial cell medium EGM-2. For FACS
analysis, we examined CD31, CD144, CD34, CD133, and Flk-1,
which are known to be markers for endothelial differentiation of
ES cells [10,12]. As expected, CD31 and CD144 were upregulated
during the two-step differentiation and expressed robustly after
sorting (Figure 2A). In contrast, the embryonic marker Oct-4 was
downregulated during hESC-EC differentiation (data not show).
We also observed Flk-1 and CD133 were expressed at high level
on undifferentiated hESCs (Figure S1), consistent with previous
reports [10,12]. hESC-ECs morphologically resembled HUVECs,
which were uniformly flat, adherent, and cobblestone-like in
appearance. When CD31
+/CD144
+ cells were cultured in
endothelial growth medium, the majority of cells were adherent
and expressed endothelial markers (CD31, CD144) at the
endothelial cell adherent junctions as well as von Willebrand
factor (vWF) located within the cytoplasm (Figure 2B). The
CD31
+/CD144
+ cells also uptake DiI-acetylated low-density
lipoprotein, and rapidly formed vascular network-like structures
when placed on Matrigel (Figure 2C). Taken together, these data
confirm that these differentiated cells were of endothelial lineage.
Gene profiles of hESC-EC differentiation
In order to define at a molecular level the changes occurring at
each stage of hESC differentiation into endothelial cells, we next
performed transcriptional profiling using whole human genome
microarrays on (i) undifferentiated hESCs, (ii) day-12 EBs, (iii)
hESC-ECs after CD31/CD144 sort, and (iv) HUVECs as positive
control (n=4/group). The resulting data were analyzed using
GeneSpring GX 7.3.1 to identify genes which had changed
expression significantly between stages. A summary of our major
findings is shown in Figure 3A. To obtain an overview of the
transcriptional landscape, we looked at the data using principal
components analysis (PCA), a dimensional reduction technique
which identifies ‘‘principal components’’ or major trends in gene
expression in the overall data (Figure 3B). PCA demonstrates that
each of the four replicates from each stage has very similar
transcriptional profiles to one another, but distinctly different
between stages, as expected. A hierarchical clustering overview of
the microarray experiments as a whole (Figure 3C) likewise shows
that the overall gene expressions among replicates of each stage
are very similar, with progressive differences between more
distantly separated stages. Of particular interest is the close
clustering of hESC-ECs and HUVECs, indicating a high degree of
similarity between their respective expression profiles. Using K-
means clustering analysis (Figure 3D), we can easily identify four
major trends in the microarray data. Additional analysis and data
can be found in Supplemental Microarray Analysis S1 and
Tables S1, S3, S3, and S4.
qPCR confirmation of microarray results and analysis of
specific gene expression changes on sprouting EBs in
collagen
To investigate changes in endothelial related genes during
endothelial cell differentiation in collagen, we performed quanti-
tative real-time PCR analysis using the Human Endothelial Cell
Biology PCR array on undifferentiated hESCs, EBs, EB sprouting,
hESC-ECs, and HUVEC as a positive control. Analysis of scatter
plot demonstrated 28 genes were upregulated when day-12 EBs
were embedded into collagen type I for an additional 3 days
hESC-Derived Endothelial Cells
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were upregulated and 8 genes downregulated after undifferenti-
ated hESCs differentiated into EBs, and 33 genes upregulated and
2 genes downregulated after hESCs differentiated into EB
sprouting. Quantitative analysis showed after endothelial induc-
tion, ICAM1, CD31, VCAM1, and vWF were significantly
upregulated, while FGF1, Flt1, KDR and VEGFA were expressed
in undifferentiated cells and upregulated with endothelial
differentiation of hESCs (Figure 4B), which were also consistent
with the microarray data. To explore the mechanism of promotion
of endothelial differentiation in collagen, quantitative analysis was
carried out and showed that endothelial cell activation genes were
upregulated swiftly and endothelial differentiation was triggered
after hEBs were embedded into collagen (Figure 4C).
In vivo vasculogenic potential of hESC-ECs
To evaluate whether hESC-ECs are capable of forming
functional blood vessels in vivo, we used Matrigel plug and tissue-
engineered vessel models in immunodeficient SCID mice that
allow dynamic and long-term observation of blood vessels derived
from implanted cells [8,17]. For Matrigel plug assay, two weeks
after subcutaneous injection, Matrigel plugs were harvested and
histology performed. Hematoxylin and eosin (H&E) staining
showed microvessels that contained murine blood cells in the
vessel lumens. Harvested Matrigel plugs were also stained with
anti-human CD31 and anti-GFP antibodies (Figure 5A). For
tissue-engineered vessel formation assay, hESC-ECs were cultured
in collagen and Matrigel for one day and tube-like structures can
be formed (Figure 5B–I). After the collagen and Matrigel patch
was implanted into mouse dorsal windows (Figure 5B–II), cord-
like networks formation by the GFP-labeled hESC-ECs can be
observed by intravital microscope (Figure 5B–III). To test
whether the engineered vascular networks integrated with the host
murine circulatory system, we next injected Angiosense 680
intravenously to enhance the contrast of perfused vessels.
Importantly, several of the hESC-EC derived vessels formed
conduits that contained blood flow from day 12 to day 60
(Figure 5B, III–VI). Importantly, these data suggest that
transplanted hESC-ECs have angiogenic potential and are able
to integrate into the host vasculature without co-transplantation of
supporting fibroblasts (Video S1).
Assessment of left ventricular function following hESC-EC
transplantation
Previous studies have demonstrated that hESC-derived cardio-
myocyte transplantation can improve cardiac function after
myocardial infarction [24,25]. To understand the therapeutic
potential of hESC-ECs for treatment of ischemia heart disease, we
subjected adult SCID mice to LAD ischemia-reperfusion followed
by injection with either 1610
6 hESC-ECs (n=28) or PBS (n=15).
For sham operated animals (n=5), open thoracotomy was
performed without LAD ligation and without injection of hESC-
ECs or PBS. Echocardiograms were performed at baseline, day 2,
day 14, day 28 and day 56 post transplantation (Figure S2). At
day 2 following infarction, there was a significant decrease in the
fractional shortening (FS) in both the hESC-EC treated group and
Figure 2. In vitro characterization of hESC-ECs. (A) During hESC differentiation and endothelial isolation, FACS analysis shows CD31 and CD144
increase significantly. (B) Morphogenesis shows the cells possess cobblestone-like morphology. Histology shows CD31 and CD144 are expressed on
cell membranes, and vWF in the cytoplasm. Scale bars=20 mm (left), 10 mm (middle two), 5 mm (right). (C) Similar to HUVECs, hESC-ECs also can
uptake ac-DiI-LDL and form tube-like structures on Matrigel. Scale bars=20 mm.
doi:10.1371/journal.pone.0008443.g002
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infarction and subsequent loss of cardiac contractility. By day 14,
we observed a significant improvement in the fractional shortening
for the hESC-EC treated group compared to control group
(27.863.0 vs. 23.962.0; P,0.05). However, by day 56, there was
no significant difference between the treatment group and control
group (31.465.6 vs. 29.863.7; P=0.26).
Assessment of cardiac viability and contractility following
hESC-EC therapy
Metabolic activity and deficits in the heart can be detected using
the [
18F]-FDG radiotracer with a microPET system [22]. This
technique can be used to accurately detect changes in cardiac
viability following infarctions in small animal models [26].
Therefore, we performed [
18F]-FDG PET scans at baseline, day
2, day 14, day 28, and day 56 post infarction for hESC-EC treated
and control animals. We observed a significant reduction in
cardiac [
18F]-FDG uptake for both groups at day 2, confirming
successful myocardial infarction. At day 14, there was a significant
increase in cardiac viability (indicated by increased [
18F]-FDG
uptake) in the hESC-EC treated group compared to controls
(26.361.8 vs. 22.463.4; P,0.05). However, by day 28 to day 56
there was no significant difference between the treatment group
and control (Figure S3A–B). Analysis of the [
18F]-FDG PET
images using polar-map reconstruction revealed reduced infarc-
tion size on the hESC-EC transplantation group compared to the
PBS group at day 14, but there was no significant difference at
subsequent time points (Figure S3C–D). Overall, the trends for
changes in functional contractility and metabolic activity were very
similar based on the echocardiography and microPET imaging
Figure 3. Major themes in gene expression profiles at each stage of differentiation. (A) hESCs express high levels of pluripotency-
associated genes including Oct4, Sox2, NANOG, Lefty, and DNMT. At the EB stage, the cells express high levels of mesodermal master regulators such
as Tbx2, and BMP4 as well as very enriched levels of endothelial specific master regulators including EPAS1, TIE2, KDR, and EFNA. This population also
expresses genes from other cell layers, and many developmental genes from Wnt and homeobox families. hESC-ECs downregulate early mesodermal
genes and express more endothelial specific genes, while HUVECs have the highest levels of mature endothelial gene expression with very few other
developmental lineages represented. (B) Principal Components Analysis (PCA) shows that replicate experiments of each cell type are very similar
while differentiation groups separate significantly along components 1 and 2. (C) Hierarchical Clustering Analysis - Cells from each developmental
stage cluster relatively close to each other, with the most distance between hESCs and HUVECs. (D) K-means clustering analysis identifies major
trends in gene expression across the time course.
doi:10.1371/journal.pone.0008443.g003
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using pressure volume (PV) loops at week 8, which showed a
decrease in ejection fraction for both hESC-EC treated and PBS
control groups compared to sham non-infarcted group as
expected. However, no significant difference was seen between
hESC-EC treated and PBS control groups at week 8 (Figure S4).
This was associated with higher left ventricular end diastolic
pressure (EDP) and left ventricular end diastolic volume (EDV) in
both groups compared to sham (n=5). Interestingly, EDV is lower
in the hESC-EC group (n=8) compared to PBS group (n=6)
(P=0.03), indicating that hESC-EC transplantation may have
exerted some benefit on cardiac diastolic function. Finally, as
highlighted in Table S5, there was no significant difference in
other functional parameters (e.g., cardiac output and stroke
volume) between hESC-EC treated mice and PBS control mice.
Correlation of hESC-EC survival and cardiac recovery
In order to better understand the mechanism for lack of long-
term efficacy, we next evaluated the survival of hESC-ECs using
non-invasive bioluminescence imaging. Injection of hESC-ECs
into infarcted myocardium resulted in a robust bioluminescence
signal at day 2. However, serial imaging of the same animals out to
8 weeks demonstrated a significant decay in bioluminescence,
suggesting acute donor cell death. When normalized to the signal
on day 2 after injection, the percent bioluminescence signals were
36.8615.5 at day 4, 6.761.5 at day 7, 3.560.6 at day 14, 2.360.5
at day 28, and 0.860.4 at day 56 (Figure 6). Thus, we believe less
than 1% of transplanted hESC-ECs survived beyond 8 weeks.
Histological assessment of infarct size and hESC-EC
engraftment
Histological analysis of the myocardium was performed by
examining thin sections of the gross specimen and via immuno-
fluorescent microscopic examination. Microscopic examination
showed the presence of GFP
+ hESC-ECs within myocardium. At
day 4, clumps of hESC-ECs can be found in the interstitial spaces
between cardiomyocytes, as seen with a-sarcomeric actin (a-SA)
and GFP double staining (Figure 7A). At day 28, GFP, a-SA, and
mouse-specific CD31 triple staining revealed that some of the
hESC-ECs had formed microvessel structures, integrated with host
vasculature, and differentiated into smooth muscle but not cardiac
cells (Figure 7B–D). However, the overall frequency of GFP
+
cells was significantly decreased at day 28 (Figure 7B–C), which
is consistent with the decrease in bioluminescence signals
measured over this same period of time and likely due to massive
cell death. Moreover, immunostaining with mouse CD31 and a-
Figure 4. Quantitative PCR confirmation of endothelial gene expression in hESC, EB, EB sprouting, hESC-EC, and HUVEC. (A) Scatter
plots of the endothelial related gene-expression were compared between hESC vs EB, hESC vs EB sprouting, and EB vs sprouting. Endothelial related
genes expression was analyzed by Human Endothelial Cell Biology RT2 Profiler PCR Array. The array includes 84 genes related to endothelial cell
biology. The lines indicate the diagonal and 4-fold changes between the two samples. (B) Kinetic expression of selected endothelial genes among
hESC, hEB, hEB sprouting, hESC-EC, and HUVEC. Compared to HUVEC, hESC-ECs express abundant endothelial gene except adult endothelial gene
vWF. *P,0.05; #P,0.01 compared with HUVECs. (C) After EB embedded into collagen, endothelial differentiation was triggered. Note endothelial
activation related gene expression increased swiftly regardless of the level at the beginning.
doi:10.1371/journal.pone.0008443.g004
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EC clumps (Figure S5), which suggests no direct nutrient
transport to transplanted cells other than diffusion. Finally,
examination of the explanted hearts showed a downward trend
in infarct size and an upward trend in microvascular density
(MVD) in the hESC-EC treated group, though these differences
with controls were not statistically significant (Figure S6).
Discussion
Therapeutic angiogenesis/vasculogenesis is promising for ische-
mia diseases. Due to the limited source of endothelial progenitor
cells, hESCs represent a new and exciting avenue of angiogenic
therapy. However, traditional spontaneous 3D method by EB
differentiation of hESCs into endothelial cells is inefficient and the
2D method by co-culture with animal materials such as MEFs will
limit its future clinic usage [6,8,9,10,11,12]. Therefore, we sought
to develop an extracellular matrix (ECM) culture system for
increasing endothelial differentiation of hESCs and ensuring
animal product free cells. In the past decade, there has been an
increasing consensus that the ECM contains critical signals that
regulate endothelial differentiation and blood vessel formation
during development and disease progression [27,28,29,30,31,32].
Here we describe a two-step differentiation procedure that
takes advantage of collagen I to efficiently promote differentiation
of hESCs into endothelial lineage cells. Compared to previous 3D
EB methods [10,12], this new protocol is more efficient for
deriving hESC-ECs, and may be utilized to generate large
numbers of endothelial cells for therapeutic application. Our
qRT-PCR data confirmed that angiogenesis from EB sprouting
in collagen triggered release of gelatinase, matrix metalloprotei-
nases (MMPs), tissue inhibitors of MMP (TIMP), and upregulated
Figure 5. Demonstration of functional vessels in vivo using Matrigel plug and dorsal window chamber. (A) Matrigel plug with hESC-ECs
were implanted subcutaneous injection in the dorsal region of 8-week-old SCID mice. (I) HE stain of Matrigel plug. Some of these microvessels have
mouse blood cells in their lumen. (II–IV) 14-day Matrigel plugs were stained with anti-human CD31 (red) and anti-GFP (green) antibodies, showing
microvessels that are immunoreactive with these human-specific antibodies. Scale bars=20 mm. (B) Dorsal window chamber model in SCID mice.
GFP+ hESC-ECs were cultured in a mix of collagen and Matrigel for 1 day (left, upper panel), and implanted into dorsal windows in SCID mice (middle,
upper panel). Images were taken at day 2, 14 and 21 after implantation. After 14 days, Angiosense 680 was injected by tail vein to highlight perfused
vessels within the dorsal window. Green, hESC-ECs expressing GFP; red, functional blood vessels with contrast enhanced by Angiosense 680. Scale
bars=20 mm (middle, upper panel), 20 mm (others).
doi:10.1371/journal.pone.0008443.g005
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lial gene expression and signaling lead to events that not only
stimulate vascular morphogenesis but also promote endothelial
differentiation. Global gene expression profiling of hESCs during
directed endothelial differentiation revealed significant enrich-
ment of a number of endothelial genes and appropriate biological
processes that correspond to each differentiation stage. Results
were confirmed using qPCR analysis. Though hESC-ECs and
HUVECs revealed a high degree of similarity between their
respective expression profiles, hESC-ECs do not resemble
HUVEC completely. Previous reports have shown that hemody-
namic forces such as fluid shear stress can affect gene
transcription in vivo and in vitro [33,34]. This suggests that shear
stress on HUVEC may contribute to the discrepancy of
expression profiles between HUVEC and hESC-ECs (which
have not been exposed to hemodynamic forces during the 3-week
differentiation process). Thus, to generate more functional and
mature endothelial cells, shear stress conditioning of hESC-ECs
may be needed in the future. Importantly, our microarray
analysis provides a greater understanding of the patterns of
activation of specific genes during endothelial differentiation, and
identifies novel gene targets that may be used to enhance
endothelial differentiation in the future.
To understand whether hESC-ECs also possess vasculogenic
ability in vivo, we next evaluated the in vivo vascular formation
potential of hESC-ECs after transplantation in mouse dorsal
window chamber model. Previous data showed that supporting
fibroblast cells were needed to stabilize engineered blood vessels
[8,35]. However, there are obvious drawbacks in using mouse
support cells in the study of vessel maturation of human cell. Here
we introduced collagen type I and Matrigel, without support cells,
and showed hESC-ECs can form functional vasculature and are
stable up to 2 months post transplantation. At present, we
speculate that Matrigel, which is abundant in growth factor and
extracellular matrix other than collagen I, may help stabilize the
newly formed blood vessels.
An important observation in the present study is that the
engraftment of hESC-ECs can improve cardiac function short-
term. In recent years, several animal studies have shown that
transplantation of EPCs isolated from the peripheral blood or bone
marrow can improve cardiac function [36,37,38,39]. In this study,
we have shown that transplantation of hESC-ECs can also result in
significant improvements in cardiac function at week 2. However,
this was not sustained at a significant level beyond 4 weeks. We
believe this is likely due to massive cell death within the first few
weeks of transplantation, as indicated by our serial bioluminescence
Figure 6. Molecular imaging of hESC-EC fate after transplantation. (A) A representative animal injected with 1610
6 hESC-ECs shows
significant bioluminescence activity at day 2, which decreases progressively over the following 8 weeks. A representative control animal injected with
PBS shows no imaging signals as expected. (B) Detailed quantitative analysis of signals from all animals (n=28) transplanted with hESC-ECs (signal
activity is expressed as photons/sec/cm
2/sr). (C) Donor cell survival plotted as % signal activity from day 2 to week 8.
doi:10.1371/journal.pone.0008443.g006
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indicate that other mechanisms such as activation of paracrine
pathways may play an important role on cardiac performance
amelioration at week 2 [1], but additional studies will be needed in
the future to test this hypothesis. Indeed, one can speculate that the
acute donor cell death phenomenon may also explain the lack of
long-term functional benefits in several of the clinical trials
completed so far [40]. The reasons for acute donor cell death are
likely multi-factorial, and may involve immunogenicity due to
xenotransplantation of human cells (note SCID mice still have
natural killer cells), as well as the lack of regional nutrients and
signaling factors for maintenance of cell viability. Following direct
intramyocardial injection, the transplanted cells formed clumps as
confirmed by histology. This is in contrast to the Matrigel plug and
dorsalskin fold chamber data shown inFigure 5, whichhowever is a
static and artificial environment loaded with collagen and Matrigel,
and does not reflect the stress imposed upon hESC-ECs within a
fast-beating ischemic heart. Without adequate host blood supply,
nutrient transportation to the hESC-ECs is only by diffusion and is
likely inadequate. The survival of transplanted cells could further be
exacerbated in the context of myocardial infarction. Altogether,
these factors contributed to the loss of bioluminescence imaging
signals over time and the lack of long-term benefit in cardiac
function, which is also consistent with recent findings based on
transplantation of hESC-derived cardiomyocytes [25,41]. Because
of these obstacles, the development of a strategy to alleviate
apoptotic cell death may be of primary importance for hESC-ECs
therapy. Recent work on hESC-derived cardiomyocyte therapy
revealed that Matrigel combined with pro-survival growth factor
cocktail resulted in reliable formation of substantial myocardial
grafts and significant functional improvement [25]. Thus, tissue
engineering techniques, rather than direct stem cell transplantation,
may prove to be a more viable approach in the future [42].
In summary, our results show that (i) endothelial differentiation
efficiency was increased by a two-step differentiation of hESCs and
with animal product free procedure by using serum free culture
medium, (ii) hESC-ECs possess functional vasculogenic ability in
vivo, and (iii) transplantation of hESC-ECs can significantly
improve short-term cardiac function at 2 weeks. However, the
numbers of surviving hESC-ECs in infarcted tissue decreased
significantly after the first few weeks, demonstrating the require-
ment for close long-term follow-up in all cardiac cell transplan-
tation studies. These data suggest that prolonged heart function
recovery may require more permanent graft survival of trans-
planted cells. Alternative transplantation protocols with larger
numbers of hESC-ECs, multiple injection time points, or addition
of matrix or prosurvival factors to prevent donor cell death after
transplantation could eventually lead to the realization of sustained
enhancement of heart function post myocardial infarction.
Supporting Information
Figure S1 Flow cytometric analysis of endothelial diffe-
rentiation of hESCs. Single representative sample of triplicates
are shown here. HUVECs were used as positive control. Isotype-
matched antibodies were used in flow cytometry for background
fluorescence.
Found at: doi:10.1371/journal.pone.0008443.s001 (0.22 MB TIF)
Figure S2 Echocardiographic evaluation of cardiac contractility.
(A) Representative M-mode echocardiographic data of infarcted
Figure 7. Confirmation of engrafted hESC-ECs by immunofluorescence. (A) Fate of hESC-ECs within the recipient myocardium 4 days after
injection showed clump formation. (B, C, D) At day 28, transplanted hESC-ECs differentiate into vasculature and smooth muscle cells (arrow), and
integrate with host myocardium as confirmed by GFP, mouse CD31, a-sarcomeric actin (a-SA) and smooth muscle actin (SMA) co-staining. However,
this population became significantly rare compared to day 4 due to donor cell death. Scale bar=20 mm.
doi:10.1371/journal.pone.0008443.g007
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day 14, and day 56. (B) Comparison of fractional shortening (FS)
between the two groups 7 days before (baseline), 2 days, 14 days,
28 days, and 56 days after infarction. *P,0.05 vs. PBS group at
day 14.
Found at: doi:10.1371/journal.pone.0008443.s002 (0.30 MB TIF)
Figure S3 [18F]-FDG PET imaging of cardiac viability. (A)
Representative image in a normal mouse heart and at day 14 and
day 56 in infarcted hearts receiving PBS vs. hESC-ECs. (B)
Detailed quantitative analysis of signals from all animals
transplanted with hESC-ECs and PBS group. *P,0.05 vs. PBS
group at day 14. (C, D) Representative polar map of the
microPET images obtained from mice treated with PBS vs.
hESC-ECs. Measurements are based on 50% thresholds. *P,0.05
vs. PBS group at day 14.
Found at: doi:10.1371/journal.pone.0008443.s003 (0.28 MB TIF)
Figure S4 Functional evaluation of transplanted hESC-EC. (A)
Representative pressure volume (P–V) loops measured from sham
(n=5), hESC-EC (n=8), or PBS (n=6) treated at day 56.
Curvilinear end-systolic P–V relations in hESC-ECs treated mice
were shifted to the left, indicating enhanced contractility. (B–D)
Invasive hemodynamic assessment of ejection fraction (EF), end-
systolic pressure (ESP), end-diastolic pressure (EDP), end-systolic
volume (ESV), end-diastolic volume (EDV) in the 3 groups of mice
at day 56. *P,0.05; #P,0.01 compared with sham; &P,0.05
compared with PBS group.
Found at: doi:10.1371/journal.pone.0008443.s004 (0.12 MB TIF)
Figure S5 Confirmation of engrafted hESC-ECs by immuno-
staining. Clump formation of injected hESC-ECs was observed
and immunostaining with mouse CD31 (red) and a-sarcomeric
actin (green) at day 4 demonstrated no extension of host
vasculature into injected cell clumps. Scale bar=20 mm.
Found at: doi:10.1371/journal.pone.0008443.s005 (1.29 MB TIF)
Figure S6 Functional evaluation of transplanted hESC-EC. (A–
B) Representative Masson’s trichrome stain of hearts injected with
hESC-ECs versus PBS. There is no significant difference of the
area of fibrosis between hESC-EC and PBS groups. *P=0.14 vs.
PBS group. Scale bar=500 mm. (C–D) Quantitative analysis of
capillary density also showed no significantly difference in both
groups. Nuclear staining is identified by DAPI (blue). Data are
expressed as mean6SEM. *P=0.21 vs. PBS group. Scale
bar=10 mm.
Found at: doi:10.1371/journal.pone.0008443.s006 (0.40 MB TIF)
Table S1 Significant gene lists from microarray data.
Found at: doi:10.1371/journal.pone.0008443.s007 (6.51 MB
PDF)
Table S2 Over-represented gene ontology (GO) terms in
significant gene lists from microarray data.
Found at: doi:10.1371/journal.pone.0008443.s008 (0.90 MB
PDF)
Table S3 K-means clustering significant gene lists.
Found at: doi:10.1371/journal.pone.0008443.s009 (4.69 MB
PDF)
Table S4 Over-represented GO terms in the K-means clustering
significant gene lists.
Found at: doi:10.1371/journal.pone.0008443.s010 (1.25 MB
PDF)
Table S5 Values are means A ˆ6 SD. MI, myocardial infarction;
P–V, pressure-volume; HR, heart rate; ESP, end-systolic pressure;
EDP, end-diastolic pressure; ESV, end-systolic volume; EDV, end-
diastolic volume; SV, stroke volume; SW, stroke work; CO,
cardiac output; dP/dtmax, maximum first derivative of change in
pressure rise with respect to time; dP/dtmin, maximum first
derivative of change in pressure fall with respect to time; Tau-
Glantz, time constant of fall in ventricular pressure by Glantz
method; PAMP, preload-adjusted maximal power; Ea, arterial
elastance. *P,0.05 versus sham; #P,0.01 versus sham; P.0.05,
PBS versus hESC-EC group.
Found at: doi:10.1371/journal.pone.0008443.s011 (0.06 MB TIF)
Supplemental Microarray Analysis S1
Found at: doi:10.1371/journal.pone.0008443.s012 (0.15 MB
DOC)
Video S1 Blood flow in hESC-ECs engineered vessels.
Found at: doi:10.1371/journal.pone.0008443.s013 (0.21 MB
MOV)
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